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P urpose. Advanced glycation end products (AGK) exacerbate 
disease progression through tw o general mechanisms: modify­
ing molecules and forming nondegradable aggregates, thus 
impairing normal cellular/tissue functions, and altering cellular 
function directly through receptor-mediated activation. In the 
present study receptor for AGK (RAGK)-mediated cellular ac­
tivation was evaluated in the etiology of human retinal aging 
and disease.
Methods. The maculas of human donor retinas from normal 
eyes and eyes with early age-related macular degeneration 
(AMD) and advanced AMI) with geographic atrophy (GA) were 
assayed for AGK and RACK by immunocytochemistry. Cultured 
ARPK-19 cells were challenged with known ligands for RACK, 
AGK, and S100B, to  test for activation capacity. Immunocyto­
chemistry, real-time RT-PCR, immunoblot analysis, and the 
TUNKL assay w ere used to  determine the consequences of RPK 
cellular activation.
Results. Little to no immunolabeling for AGK or RACK was 
found in photoreceptor and RPK cell layers in normal retinas. 
However, when small drusen w ere present, AGK and RACK 
were identified in the RPK or both the RPK and photoreceptors. 
In early AMI) and GA, the RPK and remnant photoreceptor 
cells showed intense AGK and RACK immunolabeling. Both 
AGK and S100B activated cultured RPK cells, as revealed by 
upregulated expression of RACK, NFkB nuclear translocation, 
and apoptotic cell death.
Conclusions. Immunolocalization of RACK in RPK and photo­
receptors coincided w ith AGK deposits and macular disease in 
aged, early AMI), and GA retinas. Further, AGK stimulated 
RAGK-mediated activation of cultured ARPK-19 cells in a dose- 
dependent fashion. AGK accumulation, as occurs with normal
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aging and in disease, may induce receptor-mediated activation 
of RPK/photoreceptor cells, contributing to disease progres­
sion in the aging human retinas. (In ve s t O ph tha lm ol Vis Sci. 
2004;45:3713-3720) D01:10.1l67/iovs.04-0404
A though genetic and environmental factors contribute to 
_Z\_agc-rclatcd macular degeneration (AMD), specific mecha­
nisms of disease onset and progression remain unclear. Accu­
mulated macular drusen, extracellular deposits in Bruch’s 
membrane, are a risk factor for AMD.1 ' Retinal pigment epi­
thelium (RPK) dysfunction may decrease photoreceptor cell 
viability, leading to  central vision loss in AMD.3 Studies have 
shown degenerative cellular and molecular perturbations in 
RPK and photoreceptors overlying macular (and extramacular) 
drusen.3-5
In environments of oxidant stress, as in aging tissues, for­
mation and accumulation of advanced glycation end products 
(AGK) are accelerated (reviewed in Ref. 6). Kxtracellular and 
cellular proteins are modified by the Maillard reaction,7-f* non- 
enzymatic reactions of aldehyde groups of sugars and eamino 
groups in proteins, forming Schiff bases and Amadori adducts. 
Subsequent rearrangement reactions form stable, irreversibly 
bound AGK. The auto-oxidation of polyunsaturated fatty acids 
(PUFAs) can also contribute to carboxymethyllysine (CML) 
AGK formation.91” CML-AGK is a known marker for oxidatively 
stressed tissues in many diseases. Cross-linking of long-lived 
extracellular matrix proteins and the inability of cells to  de­
grade AGK intracellularly ultimately impair cellular physiology.
Disease progression by the formation of AGK is further 
mediated by chronic cellular activation induced by the AGK 
receptor (RACK).11 RACK is typically upregulated in response 
to injury or inflammation, effecting localized tissue repair and 
reinstating homeostasis. RACK, a member of the immunoglob­
ulin superfamily of cell surface molecules, interacts w ith sev­
eral ligands, including AGK, amyloids, SlOO/calgranulins, and 
amphoterin. Knhanced formation and accumulation of RACK 
ligands, as occurs in aging and chronic disorders, provides a 
trigger for prolonged cellular activation by RACK. Sustained 
RAGK-mediated cellular activation has been shown to contrib­
ute to disease progression in diabetes, Alzheimer’s disease, 
rheumatoid arthritis, elastosis, pulmonary fibrosis, and various 
cancers.12-17 AGK and other RACK ligands activate p21ras, MAP 
KRK1/2 kinases, and NFkB nuclear translocation, altering ex­
pression of genes involved with cellular stress.17 RACK expres­
sion is upregulated by this pathway, initiating a positive feed­
back loop sustained by continued ligand availability. 
Klucidation of RAGK-mediated alterations in gene expression of 
adhesion molecules, cytoskeletal and matrix proteins, inflam­
matory cytokines, and apoptosis mediators has been instru­
mental in linking mechanisms of cellular activation to  disease 
progression.
AGK have been reported to  accumulate in aging and AMD 
eyes in Bruch’s membrane, drusen, subfoveal neovascular 
membranes, and RPK cells.1**-19 However, in previous studies, 
specific RAGK-mediated RPK cellular response to  these adja­
cent regions of AGK deposition was not addressed. Of note, 
Hammes et al/ 0 showed CML-AGK, RACK cellular-activating
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events (including NFkB nuclear localization) in neovascular 
membranes excised from patients w ith w et AMI). However, in 
that report, the excised subretinal membranes w ere highly 
fibrotic and did not include an identifiable neuroretina. Fur­
thermore, the RAGF-positive cells w ere identified as infiltrating 
macrophages. Comparative RAGF labeling in RFF and photo­
receptor layers from earlier stages, normal aged and dry AMI) 
retinas, was not examined.
Based on evidence of RFF dysfunction, oxidative stress, and 
adjacent regions of AGF accumulation in aging and AMI) eyes, 
AGF/RAGF-mediated RFF cellular activation may play a role in 
disease progression. Therefore, earlier stages of aged and AMI) 
macular sections w ere examined for endogenous RFF AGF/ 
RAGF expression before end-stage AMI) and RFF cells were 
tested in culture for RAGF-mediated cell responsiveness.
M a ie k ia i  s ajnd M e t h o d s  
Im m unocytochem istry
Cryostat. sections (10-12  fxm thick) of maculas of tw o donors with 
early AMD. three with GA. and one with drusen and seven aged normal 
donor eyes w ere obtained from the FFR Eye Donor Program. The study 
was conducted in accordance with the guidelines in the Declaration of 
Helsinki for research involving human tissue. Macular tissue sections 
from donors with early AMD and from aged control and drusen- 
containing eyes w ere identified by histopathology. clinical records, or 
both. Antibodies to AGE (Clone No. 6D12: Wako Bioproducts. Rich­
mond. VA). RAGE N42-59 (Research Diagnostics Tnc.. Flanders. NJ). 
and phospho-T«B-« (Cell Signaling Technology. Beverly. MA), were 
used according to manufacturers' suggested concentrations. Because 
of the  inherent autofluorescence of lipofuscin in aging RPE and drusen 
in AMD eyes, streptavidin biotin peroxidase immunocytochemistry 
was performed (Universal Quick Kit and AEC kit: both from Vector. 
Burlingame. CA). Preimmune serum (10%) or preabsorption of the 
antibody with corresponding peptides (20 fxg/mL) w ere used to con­
firm antibody specificity (Fig. 1 J. inset.) RDT (N42-59) hRAGE. and 6D12 
AGE antibodies w ere used for immunocytochemical detection of RAGE 
and AGE. respectively. 6D12 has been used to study AGE formation in 
aging and AMD eyes.18-20 Because a limited num ber of sections from 
donor eyes w ere available, not all specimens could be assayed for AGE. 
Seven of 13 retinas, including age-matched normal, early AMD. and GA 
retinas w ere assayed for both AGE and RAGE.
ARPE-19 Cell Culture
ARPE-19 cells w ere grown in 10% fetal bovine serum (FCS)/RPMT 1640/ 
gentamicin (Tnvitrogen-Gibco. Carlsbad. CA). Cells w ere seeded in 
six-well plates coated with a 1:16 dilution of low growth factor syn­
thetic basement membrane (Matrigel: BD Biosciences. Bedford. MD) in 
RPMT1640 medium. On confluence, the  cells w ere incubated in 1% 
fetal calf serum (FCS)/RPMT1640/gent.amicin for at least 2 to  3 weeks 
before treatments, to allow for differentiation. AGE-bovine serum al­
bumin (BSA). BSA. or S100B (Sigma-Aldrich. St. Louis. MO) was added 
to the medium at 0-. 2-. 5-. 10-. and 25-fxM concentrations for dose- 
response experiments. Cells w ere treated for 1 to 6 days. Control wells 
w ere treated with a 1:1000 dilution of a RAGE N-42-59 (Research 
Diagnostics Tnc.) antibody, which was generated against amino acids 
42-59 located in the extracellular ligand binding domain of the recep­
tor. On completion of the experiments, cells w ere fixed and processed 
for immunocytochemistry and TUNEL assays.
AGE-BSA Preparation
Fatty acid-free BSA (5.0 mg/mL: Sigma-Aldrich) was incubated with 33 
mM glycolaldehyde (Sigma-Aldrich) in PBS for 5 days at 37°C. accord­
ing to  the protocol of Nagai e ta l.21 Glycolaldehyde modification of BSA 
has been shown reproducibly to bind RAGE with high affinity.22 The 
AGE-BSA product was dialyzed in PBS for 4 days to remove unbound
glycolaldehyde before cell treatments. AGE modification was con­
firmed with W estern blot using the 6D12 antibody (Wako Bioproducts) 
recognizing AGE-modified products, including CML-AGE. The BSA con­
trol sample showed no labeling with the AGE antibody.
Real-Time RT-PCR
A commercial system (Opticon: MJ Research. W atertown. MA) was 
used for quantifying RAGE transcript levels in ARPE-19 cell experi­
ments. Total RNA was then extracted (RNeasy: Qiagen. Valencia. CA). 
RT-PCR was performed QuantiTect. SYBR Green RT-PCR: Qiagen) on 
150 ng total RNA from each sample, followed by PCR amplification of 
specific RAGE transcripts. The RAGE primers w ere designed to identify 
only the full-length product using a 5' primer straddling splice junc­
tions for exons 1 and 2 and 3' primer exons 3 and 4 (RT-RAGEf 5'-GCT 
GGA ATG GAA ACT GAA CAC AGG-3': RT-RAGEr 5'-TTC CCA GGA 
ATC TGG TAG ACA CG-3'). Standard curves w ere generated from 0 to 
500 ng total RNA from untreated groups. 18S internal standards (3:7 
primer to competitor: QuantumRNA: Ambion. Austin. TX) w ere am­
plified in parallel samples for normalizing the RAGE signal to equiva­
lent 18S signal. Results are represented as RAGE levels (arbitrary 
fluorescence units) relative to that, of the  BSA control. The resultant, 
graph represents data from three separate experiments, duplicate 
wells assayed in triplicate.
TUNEL Assay
Cells w ere assayed for apoptosis (APO-BRDU-THC kit.: Phoenix Flow 
Systems. San Diego. CA). TUNEL-positive cells are reported as a per­
centage of total cell counts per well. At. magnification 250X. total and 
apopt.ot.ic cells w ere counted from five random visual fields for each 
four- to six-well treatment, in two separate experiments.
W estern Blot
Tn parallel experiments, cells w ere removed from synthetic matrix 
(Matrigel: BD Biosciences) with dispase (2.4 U/mL: Sigma-Aldrich) and 
sonicated in lysis buffer (50 mM Tris-HCl [pH 7.4]. 150 mM NaCl. 1 mM 
EDTA: and 0.1% Triton X-100. 1 mM phenylmethylsulfonyl fluoride 
[PMSF], and 1 X protease inhibitor cocktail: Roche Diagnostics. India­
napolis. TN)- Protein concentrations w ere determined with the Brad­
ford assay. Fifteen micrograms protein from each sample was sepa­
rated on a 12% SDS-PAGE. transferred onto nitrocellulose filters, and 
probed with 1:100 dilution anti-RAGE (Santa Cruz Biotechnology. Santa 
Cruz. CA) or 1:1000 dilution anti-RAGE (Chemicon. Temecula. CA). 
These antibodies allow for specific detection of full-length RAGE, 
unlike the N42-59 N-terminal RDT RAGE antibody that, detects secretory 
RAGE in addition to full-length RAGE. Results are representative blots 
from triplicate wells for three separate experiments.
R e s u l t s
AGE and  RAGE in  Aged Norm al Retinas
As observed by Hammes et al.,~° RAGF immunolabeling was 
present in the plexiform and ganglion cell layers, as well as 
cells in the inner nuclear layer. RAGF labeling in the inner 
retina or choroid ranged from slight to intense labeling in 
normal aged maculas. We found that regional variation in AGF 
and RAGF immunolabeling within the sections provided an 
internal control for our study. For example, a normal donor 
retina (82 years old) showed, within a region containing no 
obvious disease, some AGF labeling in the RFF, but little reac­
tivity within the photoreceptor layer (Fig. 1A). Adjacent re­
gions with drusen, had additional labeling especially evident 
within the inner segments (IS) of photoreceptors (Fig. IB). 
Sections with no disease had little to no RAGF labeling in the 
RFF or photoreceptors (Figs. 1C, IF). Adjacent regions with 
AGF immunoreactivity had enhanced RAGF signals in the RFF 
and photoreceptor IS (Figs. 11), IF). Labeling for both AGF and
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F ig u r e  1 . Im m unocytochem istry  
for AGE and RAGE in macular sec­
tions from age-matched retinas. Im- 
munopositive signal is red. (A, B) 
AGE TCC and (C, D) RAGE TCC in 
similar regions from an 82-year-old 
age-matched normal donor retina.
(A) AGE labeling was apparent be­
tween Bruch's membrane and the 
RPE but absent in photoreceptors.
(B) In an adjacent region with drusen 
(# ), AGE-immunopositive labeling 
was also present in the photorecep­
tor IS region. (C, I)) Corresponding 
regions immunolabeled for RAGE. In
(C), the RPE and photoreceptors 
showed little RAGE immunolabeling, 
but in the adjacent region (I>) with 
drusen (# ), there was RAGE immu­
nolabeling in RPE and the IS of the 
photoreceptors. (E, F) Higher magni­
fication of RAGE labeling in RPE and 
photoreceptors from (C) and (IT). 
(G-J) RAGE labeling for another age- 
matched control retina (74 years 
old). (G) Sparse, diffuse labeling for 
RAGE in the RPE and no labeling 
w ere shown in the photoreceptor IS 
or ONT.. (H) In the same macular 
section, there was RAGE label in the 
RPE over drusen (* ). (I, J )  Higher 
magnifications from (G) and (H). (J, 
inset) A 74-year-old macular section 
showed no immunolabeling when 
antibody was preabsorbed with pep­
tide (20 /Ag/ml,). Cell nuclei were 
stained with methyl green. Scale 
bars, 25 (im.
RACK was found on both apical and basal sides of RPK cells but 
was also primarily associated with the photoreceptor IS. The 
outer segment and outer nuclear layers had little reactivity for 
either AGK or RACK in sections from this retina. AGK labeling 
was particularly heavy in the cytoplasm of unidentified cells in 
the INL but there was no RACK labeling in corresponding 
sections. The OPL was relatively positive for both AGK and 
RACK in all retinal regions. In comparison, RACK immunola­
beling was very low throughout the retina of a normal 74-year- 
old donor, with light labeling in cells of the choroid and 
plexiform layers and occasional labeling in INL cells. However, 
RPK cells showed enhanced RACK signal in an adjacent region 
with drusen but no obvious label in photoreceptor cells (Kigs. 
1G-J). Results if RACK immunocytochemistry (ICC) on normal 
eyes are summarized in Table 1.
AGE Products and  RAGE in  GA and  AMD Retinas
AGK immunolabel was evident throughout the sections of GA 
maculas. One GA macula (76 years old) showed a thickened 
Bruch’s membrane and large drusen with AGK on basal and 
apical sides of RPK cells. In addition, a region of this macula 
with a relatively intact photoreceptor cell layer showed AGK 
labeling in the IS region and some localization around outer 
nuclear layer (ONL) nuclei. RACK signals w ere essentially iden­
tical with those of AGK within this region (Kigs. 2A-D). Intense 
labeling was also evident for both AGK and RACK in the
choroid, possibly reflecting monocyte/macrophage infiltration 
due to a region of choroidal neovascularization (not shown) 
reported in this donor. An older donor with GA (85 years old) 
had intense AGK labeling in the atrophied photoreceptor and 
the RPK cell layers (Fig. 2F). A corresponding region showed 
an identical profile of RAGF labeling in the RPF and throughout 
the photoreceptors cell layers, including the outer segments 
(OS), IS, and ONL (Figs. 2F-H). AGK labeling was intense in 
Bruch’s membrane overlying large drusen. The choroid had 
weak AGF and RAGF labeling. AGF-positive cells in the INL also 
had weak RAGF labeling.
Retinas of eyes with early AMD showed AGF/RAGF profiles 
similar to those in GA donor eyes. AGF (Fig. 21) and RAGF 
(Figs. 2J-L) labeling was correspondingly found in RPF and 
photoreceptor IS and ONL (when present). In both AMD eyes, 
choroidal cells showed intense labeling for both AGF and 
RAGF. Results for RPF and photoreceptor labeling in GA and 
AMD eyes are summarized in Table 1.
ARPE-19 Cell Activation
Cultured ARPF-19 cells w ere treated with AGF-BSA and 
equimolar concentrations of BSA control. AGF-BSA was made 
as previously described.21 A Western blot using the 6D12 
antibody demonstrated AGF- BSA product generation as op­
posed to the unmodified BSA control (Fig. 3A).
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T able  1 . Summary of RPE and Photoreceptor AGE and RAGE Immunolabeling in Normal Aged, Early 
AMD, and GA Retinas
A ccession # Age Case D rusen RPE RAGE P h o to re ce p to r  RAGE
99-11-23 58 Normal N - _
0012A151 73 Normal N - / +
6-23-00 74 Normal Y 4 _
00-0164 75 Normal Y 4 +
00-46 78 Normal Y 4 +
95-10 79 Normal Y
AGE/RAGE AGE/RAGE
1-41 82 Normal Y 4 /4 + /+
99-35 76 Drusen Y ^ + /+
00-48 76 Ci A Y 4 /4
99-30 85 Ci A Y ^ + /+
00-11 94 Ci A Y 4 /4
FFB*678 95 AMD (dry) Y ^ + /+
FFB*577 70 AMD (dry) Y NA
n -  13.
Twenty-five-micromolar AGH concentrations induced total 
cell death within 24 to 48 hours. Data shown are results from 
ARPK-19 cells exposed to 2 to 10 /xM AGH concentrations, 
collected after 4 days' exposure to respective treatments. To 
show that AGH induce receptor-mediated cellular activation, 
ARPK-19 cells w ere assayed for downstream effects known to 
be mediated by RACK.15-17 To examine this interaction in 
ARPK-19 cells, phosphorylated IkB-« was used as a marker for 
NFkB nuclear translocation. IkB-« is an inhibitory molecule 
that binds and sequesters the transcription factor NFkB to the 
cytoplasm when unphosphorylated. On phosphorylation, 
IkH-h releases NFkB for nuclear translocation and subsequent 
gene transcriptional regulation.23 Treatments w ith micromolar 
AGK-BSA revealed strong immunopositive signal for the phos­
phorylated form of IkH-h. unlike the BSA control-treated cells 
(Fig. 3B). These results indicate that exposure to AGH induces 
NFkB nuclear activation in RPK cells.
In d u ction  o f  A p op to sis  in  AMPE-19 Cells
ARPK-19 cells w ere examined for RAGK-ligand-induced apo­
ptosis. Both RACK ligands, AGK and S100B, w ere used as 
RAGK-specific ligands in the treatments. S100B is a central 
nervous system (CNS) neurotrophic factor at normal concen­
trations but is reported to be neurotoxic at higher concentra­
tions. Treated ARPK-19 cells showed altered morphology and 
regions of cell clumping in contrast to the more differentiated 
phenotype (Fig. 3C). Micromolar concentrations of AGK-BSA 
and S100B induced apoptosis (Fig. 3C, arrows). Results in 
Figure 3D summarize TUNKL-positive reactions after 4 days of 
2- and 10/j.M AGK-BSA and S100B treatments. These results 
show a concentration-dependent increase in TUNKL-positive 
cells in response to AGK and S100B over that w ith untreated, 
BSA, or RACK antibody treatments alone. Apoptosis was effec­
tively inhibited by cotreatm ent w ith RACK antibody (RDI anti-
95 Yr(AMD) _  —  -eKcsfc a
Corresponding region show ing intense label for RAGE in RPE, IS, and 
label in RPE (a rrow heads) and photo recep to rs {arrows). Cell nuclei w ere stained w ith methyl green
* t '
ONI. regions o f photoreceptors.
Figure 2. Im m unolocalization of 
AGE and RAGE in early AMD and 
GA retinas. (A) Retinal section from 
a 76-year-old patient w ith GA and a 
small area o f CNV (not shown in 
this section). AGE is labeled in RPE 
and pho to recep to rs. (# )  Druscn.
(B) Corresponding region in an ad­
jacent section show ing RAGE label­
ing in RPE and IS of photorecep­
tors. (C, D) Higher magnification 
show ing RAGE label in RPE (C, a r­
row head) and pho to recep to rs (D, 
arrow s). (E, F) Sections from an 
85-year-old w ith GA. (# )  Druscn.
(E) AGE labeling in basal deposits 
and B ruch’s m em brane {arrow ). 
AGE labeling was also evident in 
RPE and rem nant photoreceptors.
(F) C orresponding section show ing 
RAGE label in RPE and rem nant 
p h o to re c e p to rs . (G , H ) H igher 
magnification o f RAGE label in RPE 
(G, arrow head) and pho to recep­
tors (H, arrow ). (I, J )  Sections from 
a 95-year-old eye w ith early AMD. 
This region is adjacent to an area of 
p h o to recep to r cell loss. (I) AGE la­
bel in RPE and photoreceptors. (J)
(K, L) Higher magnification o f RAGE
. Scale bars, 25 fxm.
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Figure 3. ARPE-19 cell culture ex­
periments. RAGE-mediatcd effects in­
duced by 4-day AGE-BSA and S100B 
treatments. (A) Western blot of de­
creasing BSA and AGE-BSA concen­
trations (12.5-1.5 jug) probed with 
the 6D12 antibody that preferentially 
recognizes CMI.-modified AGE. CMI,- 
BSA signal was found only in the 
AGE-BSA preparation (modified BSA 
monomers of approximately 66 kDa 
and increasing sizes, due to AGE 
modifications and oligomer cross­
linking. w ere detected). (B) Phos- 
pho-T«B-a labeling was observed in 
confluent ARPE-19 cells treated with 
2 fxM AGE-BSA (right) bu t not with 
BSA (left). Tmmunopositive signal 
shows phosphorylated T«B-a. indica­
tive of NFkB nuclear translocation.
Inset, higher magnification. Nuclei 
w ere stained with methyl green. (C)
TUNEI.-positive (arrows) ARPE-19 
cell labeling (2 fxM AGE-BSA and 
S100B treatm ents o f confluent cells) 
was prevented by anti-RAGE anti­
body treatm ents. Also note. AGE-BSA and S100B treatm ents induced cells to  aggregate in addition to undergoing apoptosis. Nuclei w ere stained 
with methyl green. (D) Graph of percentage of TUNFJ.-positive cells after 2- and 10-fxM treatm ents (ti = 5. each) for BSA control and untreated 
wells and AGE-BSA and S100B all with o r w ithout anti-RAGE pretreatments.
hRAGK, 1:1000 dilution) in the medium. This antibody binds to 
the receptor extracellular ligand-binding epitope, preventing 
receptor interaction with AGK and S100B ligands. These results 
demonstrate that induction of ARPK-19 cell apoptosis by AGK 
and S100B ligands is mediated through RACK.
Induction o f RAGE in  ARPE-19 Cells
Because AGK-BSA activated NFkB nuclear localization, treated 
cells w ere further assayed for alterations in RACK expression 
by real-time RT-PCR. Primers w ere designed to identify only 
full-length RACK mRNA and not the splice variants that do not 
contain all domains necessary for cell activation.21 At 4 days of 
treatment w ith 2 /xM AGK or SI 00B there was a sixfold increase 
in RACK transcripts (Figs. 4A-C). Notably, cells treated with 
anti-RAGK showed inhibition of upregulation of RACK mRNA 
levels. ARPK-19 cells w ere also assayed for AGK and S100B 
induction of RACK protein (Fig. 41)). Treatments with 2 /xM 
AGK and S100B increased RACK protein levels, as detected by 
Western blot, which was not apparent with the control BSA- 
treated group. RACK is differentially spliced and glycosylated 
among various cell types, resulting in different mobilities in 
SDS-PAGH and altered size detected with Western blot.21 The 
RACK antibody (C-19; Santa Cruz Biotechnology7; recognizing 
the cytoplasmic epitope in the C terminus and specific for the 
full-length and shorter N-truncated isoforms) recognized a 
band migrating at approximately 50 kl)a.15’21 This band corre­
sponds to the full-length RACK protein containing the extra­
cellular ligand binding, transmembrane, and intracellular signal 
transducing domains. Pretreatment with RACK antibody (R1)I) 
also inhibited upregulation of the full-length RACK protein (Fig. 
41)).
D isc u ssio n
Although oxidative stress and RPK dysfunction are generally 
believed to prom ote disease progression in AMI), specific 
mechanisms governing these events are not well under­
stood. The inherently high arterial O ,  tension environm ent, 
production  of radicals in phototransduction, accum ulation 
of photooxidative lipofuscin containing A2K in the RPK, and
loss of cellular antioxidant capabilities collectively contrib­
ute to oxidative stress in the aging eye.25-29 Correspond­
ingly, RPK and choroidal cells alter the expression of genes 
for cytokines, matrix organization, cell adhesion, and apo­
p tosis.30 ~37 Chronic cellular activation perturbs normal 
structural and physiological integrity7 and may induce focal 
inflammatory responses at the RPK-Bruch’s m em brane bor­
der.30
The formation of AGK, such as CIVIL and pentosidine, is 
accelerated in regions of oxidative stress.6 AGK has been 
implicated in AMD’s pathogenesis, accum ulating in aging 
and AMI) retinas at pathologic sites in Bruch’s m em brane 
and the RPK.1S~2°-3S AGK formation w ithin extracellular ma­
trices has been proposed  to contribute to dim inished barrier 
and filtration properties in Bruch’s m em brane. Glycoxida- 
tion and lipoxidation reactions induced by oxidative stress 
have been linked to drusen formation and are proposed to 
contribute to the progression of AMI).39 In this study, the 
additional role o f AGK in RAGK-mediated cellular activation 
was exam ined as a possible contributing factor to progres­
sion.
Although a limited num ber of donor eyes w ere available 
for this study, AGK and RACK imm unolabeling show ed a 
good correlation w ith histopathologic severity. RACK label­
ing in RPK cells adjacent to drusen in o therw ise normal aged 
maculas suggests that this may be a mechanism involved in 
localized damage. This is consistent w ith the role that RAGK- 
induced cellular activation plays in reinstating hom eosta­
sis—for example, in recruiting m acrophages to sites o f in­
jury or inflammation. Strong immunolabeling in both  RPK 
and pho to recep to r layers in early AMI) and GA maculas 
suggests that chronic activation through AGK/RAGK may be 
involved in disease progression. The appearance of AGK and 
RACK in the IS region of photoreceptors was unexpected  
but consistently seen in various stages of disease progres­
sion associated w ith pathologic features and pho to recep to r 
loss. RAGK-mediated pho to recep to r responsiveness could 
not be directly assayed because of the lack of a suitable 
culture method. RPK cell cultures show ed RAGK-mediated 
cellular activating events in response to AGK treatm ents,
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Figure 4. RAGF. expression in­
duced by AGF. and S100R ligands in 
ARPF.-19 cells differentiated for 2 to 3 
weeks in 1% FCS. (A) Induction of 
RAGF mRNA measured by real-time 
RT-PCR using RAGF primers produc­
ing a 225-bp diagnostic fragment, vi­
sualized on an agarose gel (left lane: 
1-kb ladder). The next four lanes rep­
resent amplified product using stan­
dards (500-50  ng total RNA from un­
treated ARPF.-19 cells) after 30 
cycles. The remaining lanes show 
amplified fragment with BSA. AGF. 
and S100B treatments. (B) Graph of 
fluorescence (log units) versus cycle 
threshold CCD values for standards 
(black symbols) and samples (gray 
symbols). The C(T) value represents 
fluorescent signal above background 
for each reaction. The relative quan­
tity of initial template in unknown 
samples can be calculated by com­
parison to C(T)s for standards with 
increasing template (example: 500 
ng standard C(T) fluorescent signal is 
represented at 26 cycles, whereas 
lower template quantity 250 ng fluo­
rescent C(T) signal occurs at approx­
imately 29 cycles). Relationship be­
tween template quantity and num ber 
of cycles required for a significant 
C(T) during the exponential phase of 
amplification reflects an accurate calculation of template levels in a sample. (C) Graph of compiled data from three experiments, triplicate wells 
each assayed with real-time RT-PCR in triplicate reactions. (D) W estern blot analysis show ed induction of an approximate 50-kDa band with AGF 
and S100B treatments using the C-20 polyclonal antibody, upregulation of which are inhibited by anti-RAGF. pretreatments. Note that nondiffer­
entiated ARPF.-19 cells expressed RAGF. which was downregulated in ARPF.-19 cells after 2 to 3 weeks in 1% FCS (compare nondifferentiated lane 
w ith differentiated BSA-treated lane).
including NFkB nuclear localization, apoptosis, and, of im­
portance, upregulation of the  receptor. Chronic cellular 
activation by RAC.F, altering the production of cytokines, 
grow th factors, apoptosis mediators, and RAC.F itself, is 
sustained by ongoing engagem ent of AC.F ligand w ith  the 
upregulated recep to r.15 Although a receptor-m ediated com ­
ponent was not addressed, Honda et a l.,JO show ed that AC.F 
treatm ent of ARPF-19 cells alters a similar profile of gene 
expression. AC.F has also been shown to induce synthesis of 
platelet-derived growth factor (PDGF) and VFC.F in RPF cell 
culture. j l j ~ In this context, it is im portant to  note that 
RAC.F has been shown to  regulate grow th factors and cyto­
kines (such as TNF, VFC.F, PDGF, ILs, and m onocyte che- 
m oattractant protein [MCPJ-1) m atrix organizing proteins 
(m atrix m etalloproteinases [MMPsJ), and adhesion proteins 
(vascular cell [VCAMJ and intercellular [ICAMJ adhesion 
molecules) in other aging disorders. 13~17,~7~~9,j3~j6 Future 
studies will characterize RAC.F- m ediated expression of spe­
cific genes that contribute to  RPF disease progression.
The 61)12 antibody has been characterized ' 7 and used by 
Hammes et al.~° and o thers1^  to  dem onstrate AC.F in dis­
eased macular tissues. This antibody preferentially recog­
nizes CML-AC.F, an indicator of oxidative stress in tissues, 
and an additional irreversible glycoxidation product N-e- 
(carboxyethyl)lysine (CFL). The heterogeneous groups of 
chemically modified AC.F are not all equally toxic or cell 
activating. However, the  correlative labeling of AC.F and 
RAC.F and the increased staining associated w ith retinal 
disease in this study suggest that at least some AC.F in the 
aging retina is cell activating. The dem onstrated activation 
of ARPF-19 cells after treatm ent w ith AC.F-modified BSA 
further supports this conclusion. Of note, a recent study has
shown that AC.F-modified BSA generated and dialyzed w ith 
PBS can induce oxidative stress through trace redox active 
metal ions presen t in this biological buffer. lS It is possible 
that oxidative stress in our AC.F-BSA-treated ARPF-19 exper­
iments is attributable, in part, to  trace metal ions presen t in 
PBS during generation and dialysis of AC.F-BSA, However, 
the contribution to  oxidative stress in these experim ents by 
this contam inant is thought to  be minimal for th e  following 
reasons: (1) AC.F-BSA was diluted in medium containing 1% 
FCS-containing antioxidants and metal binding molecules, 
(2) similar results w ere obtained w ith  micromolar S100B 
(which was not prepared  as AC.F-BSA in a buffer solution), 
and (3) AC.F-BSA effects w ere essentially inhibited by co­
treatm ent w ith  RAC.F antibody. Therefore, in this study, the 
prim ary RAC.F-mediated cellular-activating events w ere most 
likely induced by AC.F-BSA ligands. The precise identifica­
tion of the physiologically relevant AC.F that induce recep­
tor-m ediated cellular activation in the aging retina awaits 
future studies.
Our results support a link between oxidative stress, AC.F 
formation, and AC.F induced receptor-mediated cellular activa­
tion in the aging retina. We propose that AC.F induce RAC.F- 
mediated cellular activation in RPF and photoreceptors and 
that this activation contributes to  disease progression in AMD. 
Inhibitors of AC.F formation and RAC.F in animal models of 
atherosclerosis and diabetes dramatically inhibit disease pro­
gression, even in the continued presence of initiating 
events.15,19 The AC.F/RAC.F pathway has recently become a 
target for intervention in these aging disorders. Targeting li- 
gand/RAC.F-mediated chronic activation, before photorecep­
tor and vision loss, may provide an alternative approach for 
intervention in the dry7 form of AMD.
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